Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics 

• Under the terms of the intended acquisition:  

• • Adhera will continue clinical development of MLR-1019
• • Melior Pharmaceuticals will receive Adhera stock plus royalties

See more here